Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. reports developments across a diversified biopharmaceutical business built around a core royalty portfolio, Innoviva Specialty Therapeutics, and strategic healthcare investments. Recurring updates cover royalty revenue from GSK-related respiratory products, IST commercial performance in critical care and infectious disease medicines, and capital allocation actions such as share repurchases.
Company news also includes regulatory and clinical developments for IST antibiotics, including NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea, ZEVTERA updates, medical-conference presentations, and changes in the value of strategic healthcare assets such as Armata Pharmaceuticals investments.
Innoviva, Inc. (NASDAQ: INVA) reported third-quarter 2020 financial results, showcasing gross royalty revenues of $92.2 million, primarily from GSK's sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA®. Notably, RELVAR®/BREO® ELLIPTA® sales surged by 38% year-over-year. However, income before taxes decreased by 12% to $50.5 million. The company's total cash and equivalents stood at $474.9 million. Innoviva's investment in Entasis Therapeutics now totals 52.6%. The FDA approved TRELEGY® for asthma, enhancing growth prospects.